Barinthus Biotherapeutics (BRNS) Goodwill & Intangibles (2021 - 2026)

Barinthus Biotherapeutics has reported Goodwill & Intangibles for 6 years, with the latest figure at $13.7 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles fell 35.4% year-over-year to $13.7 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (down 35.4% YoY), and the FY2025 full-year result was $14.3 million, down 34.9% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $13.7 million, down from $14.3 million in the prior quarter.
• The five-year high for Goodwill & Intangibles was $43.3 million in Q1 2022, with the low at $13.7 million in Q1 2026.
• Historically, Goodwill & Intangibles has averaged $31.5 million across 5 years, with a median of $36.5 million in 2024.
• Annual changes were most pronounced in 2023 — Goodwill & Intangibles slipped 7.83% — and 2025, when it sank 57.34%.
• Barinthus Biotherapeutics' Goodwill & Intangibles stood at $40.5 million in 2022, then fell by 7.83% to $37.3 million in 2023, then plunged by 41.17% to $21.9 million in 2024, then sank by 34.9% to $14.3 million in 2025, then retreated by 4.35% to $13.7 million in 2026.
• The last three Goodwill & Intangibles figures came in at $13.7 million (Q1 2026), $14.3 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.